Edmund Graziani

Edmund Graziani has an extensive work experience spanning over several companies and roles. Edmund is currently serving as the Chief Executive Officer and Co-Founder of Apertor Pharmaceuticals since November 2020. Prior to this, they worked as the CEO of Apertor Labs from February 2019 to November 2020.

Their prominent experience in the pharmaceutical industry includes working at Pfizer for the majority of their career. Edmund held various roles at Pfizer, starting as a Senior Research Scientist II from June 1999 to December 2003. Edmund then progressed to become a Principal Research Scientist I from January 2004 to December 2006, followed by Principal Research Scientist II from January 2007 to December 2009, and Principal Research Scientist III from December 2009 to March 2010. Edmund also worked as an Associate Research Fellow from March 2010 to September 2015 and as a Research Fellow from September 2015 to February 2019.

In addition to their pharmaceutical experience, Graziani has also contributed their expertise to other organizations. Edmund briefly worked as a Research Scientist at Terragen Discovery from September 1998 to April 1999. More recently, they joined Grace Cathedral as the Chairman in September 2021.

Overall, Graziani has demonstrated a strong leadership background and expertise in the pharmaceutical industry, with a focus on research and development.

Edmund Graziani's education history begins with their time at De La Salle College Oaklands, where they completed their high school degree from 1985 to 1987. Following this, they attended the University of Toronto - University of Trinity College from 1987 to 1991, earning their Bachelor of Science (B. Sc.) degree in chemistry. Edmund then pursued further studies at The University of British Columbia from 1991 to 1996, obtaining their Ph.D. in chemistry. Afterward, Graziani continued their academic journey at Brown University from 1996 to 1998, where they completed a post-doctoral program in mechanistic enzymology.